(Q39127868)

9 September 2017

title

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma (English)

1 reference

9 September 2017

1 reference

1 reference

Zi-Zhen Xu

1

1 reference

9 September 2017

Wen-Fang Wang

2

1 reference

9 September 2017

Wan-Bin Fu

3

1 reference

9 September 2017

Ai-Hua Wang

4

1 reference

9 September 2017

Zhi-Yin Liu

5

1 reference

9 September 2017

Li-Yun Chen

6

1 reference

9 September 2017

Pei Guo

7

1 reference

9 September 2017

Jun-Min Li

8

1 reference

9 September 2017

publication date

28 August 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

55

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

1151-1157

1 reference

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Relapsed/refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Targeting the cancer kinome through polypharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

mTOR and cancer: many loops in one pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Inhibitor hijacking of Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Enhancing mTOR-targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.823492

10.3109/10428194.2013.823492

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference